Sign in

You're signed outSign in or to get full access.

AI

AiAdvertising, Inc. (AIAD)·Q3 2022 Earnings Summary

Executive Summary

  • Q3 2022 revenue increased 4% year over year to $1.85M and 19% sequentially, with gross profit turning positive amid a continued pivot from agency services to SaaS platform licensing .
  • Operating expenses rose materially (SG&A and salaries), driving a net loss of $2.02M; EPS was $0.00 (basic/diluted) given rounding and anti-dilution, consistent with prior quarters .
  • Management highlighted strategic wins (multi‑million GloriFi contract; VINIA ROAS +48%; Act! CRM expansion) and 11 platform license deals YTD (~$0.75M annualized), reinforcing SaaS traction .
  • No formal financial guidance or Wall Street consensus estimates were available; coverage appears limited for AIAD (S&P Global consensus not available). This limits benchmark comparisons and suggests the story is driven by execution milestones rather than estimate beats/misses .

What Went Well and What Went Wrong

What Went Well

  • Signed largest contract to date (multi‑million dollar GloriFi) to showcase CPP scalability: “This partnership represents the ideal opportunity…to deploy large budgets when companies are ready to scale.” — Jerry Hug, CEO .
  • Demonstrated measurable performance for VINIA (BioHarvest) with 48% higher ROAS, and drove “thousands of new qualified leads” for Act! CRM, evidencing platform efficacy in DTC and B2B contexts .
  • Platform licensing momentum: 11 agreements YTD, totaling >$0.75M annualized revenue; SaaS license revenue for 9M 2022 grew 817% to ~$0.5M, supporting the transition to predictable recurring revenue .

What Went Wrong

  • Profitability pressure: gross margin fell vs prior year; Q3 gross profit was $0.06M and 3% of revenue (down from 22% YoY) due to sales team build-out and higher platform/digital ad costs .
  • Expense growth: total operating expenses rose to $2.09M in Q3 (vs $1.10M prior year), compressing operating income and sustaining losses as the company invests in SaaS scaling .
  • Liquidity tightened: cash declined to $0.19M, with operating cash use of $4.18M year‑to‑date; reliance on an equity line (GHS) and short‑term receivables to meet capital needs elevates financing risk .

Financial Results

MetricQ3 2021Q1 2022Q2 2022Q3 2022
Revenue ($USD)$1,779,848 $1,199,662 $1,618,626 $1,850,456
Gross Profit ($USD)$398,236 -$336,170 -$9,162 $61,972
Gross Profit Margin %22.4% 3.0%
Total Operating Expenses ($USD)$1,098,163 $2,288,382 $2,007,618 $2,085,006
Net Income/(Loss) ($USD)$419,868 -$2,599,355 -$2,016,780 -$2,023,034
Diluted EPS ($USD)$0.00 $0.00 $0.00 $0.00
Consensus Revenue (S&P Global)N/AN/AN/AN/A
Consensus EPS (S&P Global)N/AN/AN/AN/A

Notes: Wall Street consensus estimates via S&P Global are unavailable for AIAD; no benchmark comparisons provided.

Segment/disaggregated revenue (9M view):

Segment ($USD)9M 20219M 2022
Design$1,547,936 $1,110,185
Development$214,743 $33,869
Digital Advertising$3,514,597 $3,062,541
Platform License (SaaS)$50,372 $462,149
Total$5,327,648 $4,668,744

KPIs and balance highlights:

KPIValue
Platform license agreements YTD and annualized revenue11 agreements; >$0.75M annualized
SaaS license revenue growth (9M)+817% to ~$0.5M
VINIA ROAS improvement+48%
Cash and Equivalents (9/30/22)$194,576
Accounts Receivable (9/30/22)$652,318
Deferred Revenue & Customer Deposits (9/30/22)$788,064
Operating Cash Flow (9M 2022)-$4,179,026

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
RevenueFY/Q4 forwardNot providedNot providedMaintained (no formal guidance)
MarginsFY/Q4 forwardNot providedNot providedMaintained (no formal guidance)
OpExFY/Q4 forwardNot providedNot providedMaintained (no formal guidance)
Other (tax, OI&E, dividends)FY/Q4 forwardNot providedNot providedMaintained (no formal guidance)

Earnings Call Themes & Trends

No Q3 2022 earnings call transcript was found in filings; thematic analysis is based on press release and 10‑Q disclosures.

TopicPrevious Mentions (Q1 & Q2)Current Period (Q3 2022)Trend
AI/Technology initiatives (CPP)Pivot to SaaS; launch of centrally hosted licensing; emphasis on persona‑driven targeting and predictive creative CPP V1 launched; rebranding as next‑gen AdTech; filed provisional patents Increasing emphasis
Revenue model shift (SaaS)SaaS licensing introduced; platform license revenue building; design/dev/digital advertising declining YoY 11 platform license deals; SaaS revenues +817% (9M); >$0.75M annualized licenses Strengthening
Macro/financingNegative monthly operating cash flows; reliance on equity financing arrangements; working capital swings Cash down to $0.19M; reliance on $10M equity line (amended pricing, removed $0.01 floor) Mixed (financing flexibility up; liquidity tight)
Customer concentration45–46% of revenue concentrated among few customers; AR concentrations 58–64% Continued concentration; DTC wins (VINIA) and new partners (Act!, GloriFi) to diversify Gradual diversification
Regulatory/legalNone material disclosed None material disclosed Stable
R&D/product executionR&D spend initiated and rising; platform feature enhancements Continued enhancement; IR engagement (MZ Group) and brand refresh supporting go‑to‑market Ongoing execution

Management Commentary

  • “We continued to make significant progress in our transition from operating as an agency…to a SaaS platform solution with scalable and predictable, monthly recurring revenue.” — Jerry Hug, Chairman & CEO .
  • “The quarter was highlighted by a multi‑million dollar and largest contract to date with GloriFi…represent[s] the ideal opportunity for us to showcase the efficiencies of our platform.” — Jerry Hug .
  • “Initial performance with VINIA have led to a month‑over‑month increase in BioHarvest’s budget and has helped drive triple digit revenue growth for VINIA sales in the third quarter.” — Jerry Hug .
  • “We have cemented our status as one of the most innovative…solutions and as a clear market leader in the rapidly emerging SaaS in the AdTech category.” — Jerry Hug .

Q&A Highlights

No Q3 2022 earnings call transcript was available in company filings; therefore, no Q&A themes or clarifications can be provided for this quarter [ListDocuments result; none found].

Estimates Context

  • Wall Street consensus estimates (S&P Global) for AIAD’s Q3 2022 revenue and EPS were unavailable; the company appears to have limited analyst coverage. As a result, no beat/miss analysis vs Street can be conducted this quarter .

Key Takeaways for Investors

  • Execution over estimates: With no consensus coverage, the stock’s near‑term narrative hinges on landing and expanding SaaS licenses (11 YTD; >$0.75M annualized), proof points like VINIA’s +48% ROAS, and onboarding large DTC partners (GloriFi) .
  • Margin rebuild underway: Gross profit turned positive in Q3 with 3% margin, but remains below prior year due to scaling costs; watch mix shift toward higher‑margin platform licensing to improve unit economics .
  • Liquidity watch: Cash sat at $0.19M at quarter‑end; operating cash burn of ~$4.18M (9M) necessitates ongoing use of the GHS equity line and receivables collections—monitor dilution and capital needs into 2023 .
  • Segmentation: 9M data shows SaaS license growth offset by declines in legacy design/development; sustained platform adoption is key to durable revenue and margin improvement .
  • Organizational alignment: CEO appointment, rebranding, patents, and IR program (MZ Group) support institutional engagement and commercialization messaging—important for PMs tracking potential re‑rating catalysts .
  • Concentration risks: High customer concentration persists; continued onboarding of diversified DTC/B2B clients (Act!, VINIA, GloriFi) can mitigate revenue volatility .
  • Short‑term trading implication: Headlines on contract wins, SaaS logos, and CPP performance case studies likely drive sentiment; absence of guidance/coverage means prints and announced wins can be outsized catalysts .

Citations:

  • Q3 2022 8‑K press release and financials
  • Q3 2022 10‑Q
  • Q2 2022 10‑Q
  • Q1 2022 10‑Q
  • GHS equity line amendment
  • CEO appointment 8‑K and press release